318. Citrin deficiency Clinical trials / Disease details
Clinical trials : 2 / Drugs : 2 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000038114 | 2020-09-15 | 2020-09-11 | Molecular Diagnostic Study and Clinical Management of citrin deficiency | Molecular Diagnostic Study and Clinical Management of citrin deficiency | Citrin deficiency | Gold Standard:Sanger sequncing;Index test:Next-Generation Sequncing; | Beijing Friendship Hospital Affiliated to Capital Medical University | NULL | Recruiting | Both | Target condition:60;Difficult condition:0 | N/A | China | ||
| 2 | JPRN-jRCTs041190017 | 31/07/2012 | 10/04/2019 | Confirmation of effects of medium chain triglyceride therapy for citrin deficiency | Confirmation of effects of medium chain triglyceride therapy for citrin deficiency, especially in patients with symptomatic post neonatal intrahepatic cholestasis and that with adult-onset type II citrullinemia | citrin deficiency Endocrinology and Metabolism, Pediatrics;D006111 | Medium chain triglyceride 5-15ml 3 times a day | Mitsui Tetsuo | NULL | Recruiting | Not applicable | 80age | Both | 50 | Phase 2 | Japan |